ライフサイエンスコーパス: bone pain

1 ulator of tumor growth, bone remodeling, and bone pain.

2 enomegaly, lactate dehydrogenase levels, and bone pain.

3 isms of chronic bone pain and cancer-induced bone pain.

4 idence and severity of pegfilgrastim-induced bone pain.

5 or ability to prevent pegfilgrastim-induced bone pain.

6 as initial imaging studies in patients with bone pain.

7 kets, limb deformities, muscle weakness, and bone pain.

8 odest, and they should not be used alone for bone pain.

9 included minor injection site reactions and bone pain.

10 en dosing and the role of BMAs in control of bone pain.

11 r, 186Re, and 153Sm) have been used to treat bone pain.

12 symptoms including fatigue, weight loss, and bone pain.

13 phonic acid (EDTMP), have been used to treat bone pain.

14 unotherapy and in radionuclide palliation of bone pain.

15 ave been studied in patients with metastatic bone pain.

16 safe, but nearly all donors will experience bone pain, 1 in 4 will have significant headache, nausea

17 ] vs 18 [6%]), asthenia (16 [5%] vs 8 [3%]), bone pain (16 [5%] vs 5 [2%]), and febrile neutropenia (

18 with urticarial rash, fever, arthralgia, and bone pain; 47% reported weight loss, 40% fatigue, and 21

19 hrombosis (120 mg/m2), one grade 4 joint and bone pain (480 mg/m2), one thrombocytopenia (600 mg/m2)

20 4%), fatigue (7%), thrombotic episodes (7%), bone pain (5%), and gastrointestinal disturbance (4%).

21 of 704 allocated ibandronic acid), increased bone pain (91 [corrected] [13%] vs 85 [corrected] [12%])

22 satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fevers

23 15 patients required narcotic analgesics for bone pain; after treatment, eight (53%) discontinued the

24 Bone pain, analgesic use, bone biochemical markers, perf

25 = 12 mg per deciliter [3.0 mmol per liter]), bone pain, analgesic-drug use, performance status, and q

26 nding of the molecular mechanisms of chronic bone pain and cancer-induced bone pain.

27 generation and continuance of cancer-induced bone pain and discuss these in the context of understand

28 Severe bone pain and esophageal cancer have been described amon

29 practice.An 84-year-old woman presented with bone pain and lytic bone lesions in April 2010.

30 ite the above replacement, she complained of bone pain and muscle weakness, and she continued to be v

31 ved pamidronate had significant decreases in bone pain and no deterioration in performance status and

32 ften asymptomatic but can be associated with bone pain and other complications such as osteoarthritis

33 ed by extensive osteolysis leading to severe bone pain and pathologic fracture.

34 Bone pain and radiologic evidence of periostitis were ex

35 mia in a 53 year old male who presented with bone-pain and B-symptoms and was found to have diffuse o

36 a decrease in skeletal events, palliation of bone pain, and a low profile of adverse reactions (which

37 h nephrolithiasis, significant osteoporosis, bone pain, and in some cases constitutional symptoms sho

38 getic beta-particle emitters for alleviating bone pain, and possibly for other therapeutic applicatio

39 Interventions for pegfilgrastim-induced bone pain are needed.

40 is primarily indicated for patients who have bone pain arising from increased metabolic activity in a

41 he sensory characteristics of cancer-induced bone pain as a basis for better understanding and treati

42 We now view cancer-induced bone pain as a complex pain state involving components o

43 r a substantial advantage for alleviation of bone pain as well as for specifically irradiating metast

44 ons, including fractures, hypercalcemia, and bone pain, as well as reduced performance status and qua

45 49 (52%) patients with bone pain at registration had complete resolution of pai

46 ing placebo, including a higher incidence of bone pain, bone fractures, and new-onset osteoporosis.

47 In a subgroup of patients with bone pain, CA 27.29 antigen level was found to identify

48 Palliation of bone pain can be achieved in men with androgen-independe

49 a result of osseous metastases and resulting bone pain can lead to significant debilitation.

50 Cancer-induced bone pain (CIBP) affects one third of patients with canc

51 Conservative debridement of necrotic bone, pain control, infection management, use of antimic

52 g: acute kidney injury, arterial thrombosis, bone pain, diarrhoea, myocardial infarction, pyrexia, re

53 Seventeen patients with bone pain due to metastasis were given three dose levels

54 olled trials were conducted in patients with bone pain due to metastatic prostate cancer, with diseas

55 sing Functional Assessment of Cancer Therapy-Bone Pain (FACT-BP) scores (scale, 0-60 points), improve

56 g acutely with non-specific symptoms such as bone pain, fever or swelling which are common in acute o

57 The principal toxicities were myalgias, bone pain, fever, nausea, and mild thrombocytopenia, but

58 History of bone pain, fractures, and avascular necrosis was found i

59 ter receiving 89Sr-chloride for treatment of bone pain from metastatic prostate carcinoma.

60 e is a useful intervention for patients with bone pain from metastatic prostatic cancer.

61 risks of external beam radiation therapy for bone pain (HR 0.67, 95% CI 0.53-0.85) and spinal cord co

62 On retrospective review, bone pain improved in 67% of evaluable patients, with a

63 to reversible panniculitis in 5 patients and bone pain in 1 patient.

64 And do bisphosphonates relieve bone pain in cancers other than breast cancer and myelom

65 Pharmaceutical therapy of bone pain includes nonsteroidal analgesics and opiates.

66 Treatment of bone pain includes nonsteroidal analgesics and opiates;

67 This information is crucial, since bone pain, including cancer-induced bone pain, is an are

68 74-year-old woman presented with multifocal bone pain, including pain in multiple ribs, bilateral sh

69 Bone pain is a common complication for terminal patients

70 Pegfilgrastim-induced bone pain is a significant clinical problem that may res

71 Cancer-induced bone pain is characterized by moderate to severe ongoing

72 A multidisciplinary approach in treating bone pain is generally required, 1 which includes a comb

73 l, since bone pain, including cancer-induced bone pain, is an area of high importance in pain biology

74 therapy in relieving prostate cancer-induced bone pain, is that nearly all nerve fibers that innervat

75 significantly associated with baseline PSA, bone pain, liver disease, hemoglobin, alkaline phosphata

76 Current standards of care for cancer bone pain management should be applied at the onset of p

77 Bone pain, myalgia, presyncope, or fever occurred in 55%

78 erse events in all treatment groups included bone pain, nausea, anemia, and vomiting.

79 Obese donors experienced more bone pain (obese vs normal, OR=1.73) and heavy donors ha

80 resis-related AEs (20% vs 7%, P< .001), more bone pain (odds ratio [OR]=1.49), and higher rates of gr

81 two [1%]), dyspnoea (four [2%] vs one [1%]), bone pain (one [1%] vs four [2%]), congestive cardiac fa

82 in PSA levels coupled with either relief of bone pain or by a 50% decrease in measurable disease.

83 nefit compared with placebo in palliation of bone pain or reduction of SREs.

84 he use of external beam radiation to relieve bone pain, or occurrence of a new symptomatic pathologic

85 e review data regarding atrial fibrillation, bone pain, osteonecrosis of the jaw (ONJ), atypical frac

86 There was significantly less increase in bone pain (P=0.046) and deterioration of performance sta

87 ifferent and unique and may make it an ideal bone pain palliation agent.

88 riety of therapeutic applications, including bone pain palliation and intravascular radiation therapy

89 Among the four potential bone pain palliation radionuclides, 117mSn(4+)DTPA demon

90 ide therapies such as radioimmunotherapy and bone pain palliation.

91 es are needed to determine its exact role in bone pain palliation.

92 ytic bone destruction and its complications, bone pain, pathologic fractures, and hypercalcemia, are

93 ase and/or treatment of disease, and include bone pain, pathological fractures and spinal cord compre

94 For metastatic bone pain, providers should offer single-fraction radiot

95 Currently, the treatment of bone pain remains palliative at best with systemic thera

96 ticals have shown good efficacy in relieving bone pain secondary to bone metastasis.

97 Greek patients had more bone pain than United States patients (60% v 30%, P = .0

98 flushing, palpitations, dyspepsia, diarrhea, bone pain) that can be severe and potentially life threa

99 22 y) presenting with sickle cell-associated bone pain underwent 93 sequential examinations with 99mT

100 Bone pain, use of analgesic drugs, performance status, a

101 Bone pain, use of analgesics, quality of life, performan

102 Over the years, treatment of bone pain using bone-seeking radiopharmaceuticals has be

103 Symptoms include chronic muscle and bone pain, weakness, and fatigue in association with a h

104 ild-to-moderate injection-site reactions and bone pain were more common in the sargramostim group, an

105 have metastasized to bone frequently induce bone pain which can be difficult to fully control as it

106 Thirty-one patients with metastatic bone pain who underwent FDG PET/computed tomography befo

107 amidronate (Aredia), will relieve metastatic bone pain with a consequent improvement in quality of li